Submission of Earning Call Transcript Under Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
BALAMINES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Balaji Amines reported Q4 FY25 consolidated revenue of INR 361 crores (up from INR 321 crores in Q3), with EBITDA of INR 68 crores at a 19% margin and PAT of INR 40 crores. Full-year FY25 revenue declined to INR 1,430 crores (from INR 1,671 crores in FY24), with EBITDA margin compressing to 19% from 21% and PAT falling to INR 159 crores from INR 232 crores. Standalone entity remains zero-debt. Management guided for 10-12% volume growth and improvement in EBITDA and PAT margins going forward, citing recovery in the specialty chemicals industry. Several capacity expansions are underway or commissioned, including the 8MW solar plant, methylamine, N-Butylamine, electronic-grade DMC, and a INR 750 crore greenfield project at subsidiary Balaji Specialty Chemicals in two phases.
Mixed signals for shareholders — FY25 saw revenue and profit decline, but Q4 showed sequential recovery and management is betting on new product commissions (DME pending PESO approval, NMM, acetonitrile expansion) to drive a turnaround. Stock may react to margin recovery guidance and capex execution timeline, though near-term pricing pressure from raw material inflation remains a watchpoint.